Scholars@Duke

Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581).

Publication ,  Conference
Colacchio, TA; Niedzwiecki, D; Compton, C; Warren, R; Benson, AIB; Goldberg, R; Kerr, D; Fields, A; Hollis, D; Mayer, R
Published in: JOURNAL OF CLINICAL ONCOLOGY
July 15, 2004
Link to item

Duke Scholars

Donna Niedzwiecki
Author Donna Niedzwiecki Biostatistics & Bioinformatics, Division of Biostatistics

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

July 15, 2004

Volume

22

Issue

14

Start / End Page

250S / 250S

Location

New Orleans, LA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

40th Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Colacchio, T. A., Niedzwiecki, D., Compton, C., Warren, R., Benson, A. I. B., Goldberg, R., … Mayer, R. (2004). Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 22, pp. 250S-250S). New Orleans, LA: AMER SOC CLINICAL ONCOLOGY.
Colacchio, T. A., D. Niedzwiecki, C. Compton, R. Warren, A. I. B. Benson, R. Goldberg, D. Kerr, A. Fields, D. Hollis, and R. Mayer. “Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581).” In JOURNAL OF CLINICAL ONCOLOGY, 22:250S-250S. AMER SOC CLINICAL ONCOLOGY, 2004.
Colacchio TA, Niedzwiecki D, Compton C, Warren R, Benson AIB, Goldberg R, et al. Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2004. p. 250S-250S.
Colacchio, T. A., et al. “Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581).” JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 14, AMER SOC CLINICAL ONCOLOGY, 2004, pp. 250S-250S.
Colacchio TA, Niedzwiecki D, Compton C, Warren R, Benson AIB, Goldberg R, Kerr D, Fields A, Hollis D, Mayer R. Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2004. p. 250S-250S.

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

July 15, 2004

Volume

22

Issue

14

Start / End Page

250S / 250S

Location

New Orleans, LA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

40th Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences